Mergers & Acquisitions ·
Lisata Therapeutics, Inc. entered into an amendment to its Merger Agreement with Kuva Labs Inc. and Kuva Acquisition…
LSTALisata Therapeutics, Inc.
Lisata Therapeutics, Inc. entered into an amendment to its Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp. to extend the tender offer commencement date to June 10, 2026, and the Outside Date to July 17, 2026. The amendment includes a non-refundable $1,500,000 extension fee option for Parent to extend the deadline to August 17, 2026. Lisata agreed to waive certain claims against the acquirer, including a waived interim operating payment of $250,000, provided specific payments are made. Lisata Therapeutics, Inc. is a biopharmaceutical company focused on developing clinical-stage product candidates.